PIPTAROS 4.5GM INJ
— Product

PIPTAROS 4.5GM INJ

PIPERACILLIN SODIUM + TAZOBACTAM SODIUM

PIPTAROS 4.5GM INJ is an injection of piperacillin sodium with tazobactam sodium, a broad-spectrum penicillin combined with a beta-lactamase inhibitor. It is a hospital antibiotic used for serious infections — hospital-acquired pneumonia, intra-abdominal sepsis, complicated urinary tract infection, febrile neutropenia and severe skin and soft-tissue infection.

01

Benefits

  • One of the broadest antibacterial spectra available, covering Gram-positive, Gram-negative and anaerobic organisms including Pseudomonas aeruginosa.
  • Tazobactam inhibits beta-lactamase, restoring piperacillin's activity against resistant organisms.
  • Single-agent cover for polymicrobial intra-abdominal and pelvic sepsis, where aerobes and anaerobes coexist.
  • A standard empirical choice in febrile neutropenia and hospital-acquired sepsis where the organism is unknown and delay is dangerous.
  • Extended-infusion administration improves the time above the minimum inhibitory concentration, which is what determines efficacy for beta-lactams.
02

Side effects

Not everyone gets these. Most are mild and settle as the course finishes.

Common
  • Diarrhoea or loose stools
  • Nausea or vomiting
  • Skin rash
  • Pain or thrombophlebitis at the infusion site
Less common
  • Raised liver enzymes on testing
  • Low platelet or white cell count with prolonged therapy
  • Low serum potassium
  • Fever or eosinophilia
Stop and get medical help if any of these occur
  • Swelling of the face, lips or tongue, difficulty breathing, or collapse
  • Severe, watery or bloody diarrhoea during or in the weeks after the course
  • Widespread rash with blistering or peeling skin
  • A marked fall in urine output
  • Unusual bruising or bleeding
  • Seizures
03

Precautions

  • Contraindicated in known penicillin allergy. A history of penicillin anaphylaxis is an absolute contraindication.
  • A broad-spectrum reserve antibiotic. Use empirically where serious infection demands it, then de-escalate on culture results — indiscriminate use drives resistance and Clostridioides difficile infection.
  • Dose reduction is required in renal impairment; accumulation causes neurotoxicity and seizures.
  • The combination of piperacillin-tazobactam with vancomycin increases the risk of acute kidney injury — monitor renal function closely where both are used.
  • Contains a significant sodium load — relevant in heart failure and fluid restriction.
  • Monitor blood counts, renal function and electrolytes during prolonged courses.
  • Do not mix in the same syringe or line as an aminoglycoside.
  • For administration by a qualified healthcare professional only.